Titusville, New Jersey (ots/PRNewswire) - Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A. VX-787 is an investigational ...
Paris (ots/PRNewswire) - - Findings set foundation to drive recommendations for enhancing care - Sanofi announced today the first results of the TEENs Registry Study, the largest contemporary real-world study of the care of nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings not only ...
Amsterdam (ots/PRNewswire) - - China's most important gathering of food and beverage industry professionals China's leading nutritional ingredients event, Food ingredients (Fi) Asia China, Health ingredients (Hi) and Natural ingredients (Ni), will take place this month, June 26-28 2014 in Shanghai, China. This is the premier event in China offering food & beverage ...
Paris (ots/PRNewswire) - Sanofi announced today that Lyxumia(R) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when ...
Paris (ots/PRNewswire) - - In EDITION JP I and II, investigational Toujeo(R)demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus(R)- Sanofi announced today full results from EDITION JP I and EDITION JP II that showed Toujeo(R) (insulin glargine ...
Cork, Ireland (ots/PRNewswire) - Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's ...
Paris, France (ots/PRNewswire) - - New results for Toujeo(R)(insulin glargine [rDNA origin] injection, 300 U/mL; "U300") from EDITION I/II/III meta-analysis, EDITION III, IV, JP 1 and JP 2 studies are among over 65 abstracts to be presented - Sanofi announced today that new data on U300, Lyxumia(R) (lixisenatide) ...
Darmstadt, Germany (ots/PRNewswire) - - FDA clearance validates Eeva System, which enables in-vitro fertilization (IVF) clinicians to offer the proprietary Eeva Test and further demonstrates commitment by Merck Serono and Auxogyn to bring innovative technologies to the IVF community - Eeva Test first-of-a-kind ...
Hørsholm, Denmark (ots/PRNewswire) - First sublingual allergy immunotherapy tablet with robust results in allergic rhinitis and allergic asthma. Data supports European regulatory filing in 2H 2014 Today, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has presented key trial results on its new sublingual allergy ...
Copenhagen, Denmark (ots/PRNewswire) - And highlight a decade of clinical evidence demonstrating long-term efficacy and tolerability of once-daily GRAZAX(R) SLIT-tablet at EAACI 2014 A group of eminent allergy and respiratory professors presented data specifically addressing numerous key questions within the allergy community concerning grass SLIT-tablets, with ...
Darmstadt, Germany (ots/PRNewswire) - - Development and commercialization agreement on blood-based RAS biomarker mutation status test for (metastatic) colorectal cancer (mCRC) - This non-invasive, fast and easy-to-perform diagnostic test is expected to provide a real-time reflection of a patient's RAS mutation status to help guide clinical decision making in mCRC Merck ...
Chicago (ots/PRNewswire) - Data from the ongoing Phase I AURA study in patients with epidermal growth factor receptor mutation positive (EGFRm+), advanced non-small cell lung cancer (NSCLC), demonstrate that the overall disease control rate was 94 percent for patients with EGFR T790M+ tumours - meaning that their ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of monotherapy ibrutinib showed continued ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Phase 3 data (Abstract LBA7008) featured in the official press programme of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine Data from the international, multicentre ...
Darmstadt, Germany (ots/PRNewswire) - ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 - Robust pipeline reflects commitment to innovation in oncology and immuno-oncology - Data from nine Merck ...
Takeda Pharmaceutical Company Limited
Zurich And Osaka, Japan (ots/PRNewswire) - Discovery Minerals (DSCR) Undervalued and Nearing Its SqueezeTrigger Price According to WealthMakers.com Report May 27, 2014 WEALTHMAKERS.COM / www.wealthmakers.com [http://www.wealthmakers.com ] , a Wall Street research and trading firm providing unbiased statistical stock ...
Darmstadt, Germany (ots/PRNewswire) - - For the 6th time in a row Merck Serono takes part in the International Thyroid Awareness Week with focus on HIGH FIVE - Five reasons to be aware of thyroid disease: Thyroid cancer, autoimmunity, infertility, anxiety/depression, and iodine deficiency Merck Serono, the biopharmaceutical division of Merck, together with Thyroid ...
Beerse, Belgium (ots/PRNewswire) - - Research in haematological malignancies features VELCADE(R), siltuximab, ibrutinib and daratumumab - Note: This release corresponds to EHA abstracts S1345, P958, P957, P369, P353, P960, P1211, P1209, P461, P356, P350, P434, P109 Janssen Pharmaceutica NV announced data related to ...
London (ots/PRNewswire) - Health and safety bodies unite to launch Health & Safety Week 2014 To celebrate the UK's 85% reduction in fatal accidents since the introduction of the Health and Safety at Work Act in 1974, the country's leading health and safety bodies are uniting to launch Health & Safety Week 2014, 16th - 20th June, at Safety & Health Expo and reinstate a positive image for this exceptionally worthwhile profession. (Logo: ...
London (ots/PRNewswire) - Is it really possible to develop labelling that is legally compliant, commercially viable, and influence a patient's behaviour? Pharma IQ recently worked with Dr. Karel van der Waarde, to review this question. The following article is the result - it addresses the recent falsification and ...
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract Number: 3506 - In a retrospective analysis of the Phase III CRYSTAL* study, which assessed RAS tumor status, significant clinical benefit was observed in mCRC patients with RAS wild-type tumors receiving Erbitux plus FOLFIRI, compared with FOLFIRI alone - No ...
Singapore (ots) - Since 2012 the hearing industry's largest manufacturers have collaborated to sponsor a non-competitive, mutually agreed upon research agenda benefitting the hearing aid industry, its customers, and end users. The framework for this collaboration is the Hearing Industry Research Consortium (IRC). ...
Amsterdam (ots/PRNewswire) - Indonesian pharmaceutical market to grow 6% annually Leading events organiser, UBM Live, announces the return of CPhI South East Asia. Now in its third consecutive year, the leading pharmaceutical ingredients event, co-located with P-MEC and InnoPack, will take place at the Jakarta International Expo, Indonesia from 20th to 22nd May 2014. (Logo: ...
Shire plc and Lumena Pharmaceuticals
Dublin And San Diego (ots/PRNewswire) - - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease pipeline assets - Adds to Shire's rare diseases portfolio and leverages this expertise, and is a perfect combination with Shire's already strong Gastrointestinal (GI) presence - ...
Copenhagen, Denmark (ots/PRNewswire) - For healthcare media only, not for US, UK or Spanish journalists Today, Novo Nordisk announced new phase 3 interim data from its guardian(TM)2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight(R) (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term ...
Kontich, Belgium (ots/PRNewswire) - FLUIDDA's breakthrough imaging technology was used to assess the mode of action of Roflumilast, a novel drug to treat patients suffering from chronic obstructive pulmonary disease (COPD). FLUIDDA's study clearly demonstrated that the drug was superior to placebo and very effective in a subset of patients. Furthermore, the study ...
Amsterdam (ots/PRNewswire) - Improved process efficiency, with modern manufacturing techniques could save billions and increase profits, improve quality and open up sales in developing markets Girish Malhotra, CPhI expert panel view: "'Process centricity' has to overtake the current 'regulation centricity' if pharma ...
Darmstadt, Germany (ots/PRNewswire) - - Primary endpoint met in SPARK study: significant increase in phenylalanine tolerance demonstrated after 26 weeks of the study in children less than 4 years of age with phenylketonuria and responsive to Kuvan treated with Kuvan plus a phenylalanine-restricted diet, versus diet alone - SPARK study was conducted as a post-authorization measure and results will be submitted to EMA this ...
Lyon, France (ots/PRNewswire) - European vaccine leader hosts events across the region to help raise awareness of immunization throughout life Sanofi Pasteur MSD welcomes the World Health Organization's European Immunization Week 2014 (EIW 2014) with a series of awareness-raising events across the region, taking place between April 22nd and 26th. Sanofi Pasteur MSD, the European leader for vaccines in Europe, has joined ...
Amsterdam (ots/PRNewswire) - - The global meeting place for health and wellness industry innovation Europe's leading nutritional ingredients event, Health ingredients (Hi) Europe & Natural ingredients (Ni), will take place in December 2-4 2014 in Amsterdam, Netherlands. This is the premier event in Europe offering food & beverage manufacturers and producers the opportunity to find new suppliers and source health and ...